Latest Breaking News On - Pharma marketing - Page 6 : comparemela.com

Johnson & Johnson to sell another 100M coronavirus vaccine doses to U S , taking America s supply to 800M doses: reports

Mar 10, 2021 10:24am Johnson & Johnson will sell another 100 million COVID-19 vaccine doses to the U.S., according to reports.(J&J) One year ago this week, the COVID-19 pandemic hit home with Americans when Tom Hanks revealed he had tested positive and the NBA postponed its season indefinitely. Things have changed mightily since then: A national vaccine rollout is gaining steam, and the U.S. is inking yet another huge supply deal. The Biden administration is purchasing another 100 million doses of the one-dose shot from Johnson & Johnson, according to media reports. The vaccine is just rolling out across the U.S. after an FDA authorization late last month.

United statesJustin trudeauTom hanksPharma europeJoe bidenMerck coPharma marketingDigital pharmaJohnson ampJoseph bidenMerck amp coCovid 19ஒன்றுபட்டது மாநிலங்களில்ஜஸ்டின் திருடேௌஉடோம் ஹாங்க்ஸ்பார்மா யூரோப்

PatientPoint merges with Outcome Health, combining networks and sunsetting the scandal-tainted Outcome brand

Mar 10, 2021 9:35am PatientPoint and Outcome Health are merging to form the new PatientPoint point-of-care network and company. (Alpha Stock Image) After enduring a turbulent few years, point-of-care advertising and marketing company Outcome Health is getting a makeover, thanks to a merger. PatientPoint is merging with Outcome to create PatientPoint Health Technologies point-of-care network, and in the process it s retiring the Outcome name. The combined company will be led by PatientPoint executives and CEO Mike Collette. Outcome Health CEO Matt McNally and chief operating officer Nandini Ramani are leaving the company. The denouement of the Outcome Health brand is not entirely surprising, as it brings to an end a saga that included allegations of self-dealing, audits, an investor lawsuit and more.

United statesMatt mcnallyMike colletteShradha agarwalPharma europeNandini ramaniPatientpoint health technologiesCannes lions healthOutcome healthPharma marketingDigital pharmaChicago businessWall street journalPoint of careஒன்றுபட்டது மாநிலங்களில்மேட் ம்க்நல்லி

Bayer unveils first look at its post-Xarelto, post-Eylea life—and it s better than expected

Bayer unveils first look at its post-Xarelto, post-Eylea life—and it s better than expected
fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.

Stefan oelrichPharma europePharma marketingDigital pharmaWall streetபார்மா யூரோப்பார்மா சந்தைப்படுத்தல்டிஜிட்டல் பார்மாசுவர் தெரு

NantKwest starts dosing in subcutaneous, sublingual and oral COVID-19 vaccine trials

Patrick Soon-Shiong, M.D., executive chairman of ImmunityBio and NantKwest (NantKwest) ImmunityBio and NantKwest have begun dosing participants with subcutaneous, sublingual and oral COVID-19 vaccine candidates. The trials are designed to determine which combination of routes of administration holds the most potential. While a clutch of COVID-19 vaccines are now in commercial use around the world, the potential for the coronavirus to become a pathogen that continues to circulate for years means there may be a long-term opportunity for prophylactics. ImmunityBio and NantKwest are part of a group of vaccine developers working to seize that opportunity. The partners recently took a step forward when dosing began in clinical trials in the U.S. and South Africa. Two U.S. phase 1b clinical trials are evaluating the effect of giving sublingual or oral vaccines in addition to a subcutaneous formulation. Six subjects have been dosed in each U.S. trial.

South africaSouth africanPharma europePharma marketingDigital pharmaPatrick soon shiongCorona virusCovid 19Oral vaccinesSubcutaneous drug deliveryDrug deliveryபார்மா யூரோப்பார்மா சந்தைப்படுத்தல்டிஜிட்டல் பார்மாகொரோனா வைரஸ்வாய்வழி தடுப்பு மருந்துகள்

Johnson & Johnson runs into vaccine supply issues in Europe, threatening second-quarter delivery pledge: Reuters

Mar 9, 2021 10:30am Johnson & Johnson is one of several companies working around the clock to scale up vaccine supply. (Kunal Mahto/iStock/Getty Images Plus/Getty Images) Johnson & Johnson execs have assured investors and officials that the company is comfortable hitting its vaccine delivery targets. But with its U.S. rollout underway, the pharma giant has run into some supply problems in Europe, Reuters reports. J&J’s shot isn’t yet authorized in Europe, but the company has been gearing up to supply a promised 55 million doses during the second quarter and now it s hitting some snags, an official involved in supply talks told the news service. The shot is expected to win an EU authorization in the coming days, Reuters reports, and vaccinations in the bloc could start next month.

Sanofi pasteurJoe wolkReig jofrePharma europePharma marketingDigital pharmaJohnson ampEuropean commissionCovid 19சனோஃபி பாஸ்டர்ஓஹோ வோல்க்பார்மா யூரோப்பார்மா சந்தைப்படுத்தல்டிஜிட்டல் பார்மாஜான்சன் ஆம்ப்ஐரோப்பிய தரகு